A Phase II Study of Shorter Course Hormone Therapy and Radiation for High-Risk Prostate Cancer


Full Title

Phase II Trial of Short Course Androgen Deprivation, Hypofractionated Pelvic Radiation and a Brachytherapy Boost for NCCN High-Risk Prostate Cancer with Low-Intermediate Risk Decipher Genomic Score


One of the usual approaches to treating prostate cancer that has not grown outside the prostate but has a high-risk of progressing is a combination of a medication called ADT (androgen deprivation therapy) to reduce male sex hormones combined with radiation therapy. The standard treatment schedule is 18-24 months of ADT, 5 weeks of daily radiation treatments, and brachytherapy (a procedure to place radioactive seeds near the cancer).

In this study, researchers will assess a shorter schedule of ADT and radiation to see if this approach can reduce treatment side effects and be more convenient while still being effective for treating high-risk prostate cancer. All participants will receive ADT for 6 months, undergo brachytherapy 3 months after starting ADT, and then receive 5 days of radiation one month later. 

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have high-risk prostate cancer that has not grown beyond the prostate region and has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact Dr. Daniel Gorovets at 212-639-3983.




Phase II (phase 2)

Disease Status

Newly Diagnosed



ClinicalTrials.gov ID